Hook / Thesis
Amgen (AMGN) has been marked down over the last week after Novartis disclosed that pelacarsen missed the primary cardiovascular endpoint on 09/07/2026. The market reaction was swift and indiscriminate: investors punished the whole Lp(a)-lowering complex and, by extension, Amgen, which has its own Lp(a) program (olpasiran) awaiting phase III outcomes. That knee-jerk selloff pushed AMGN back toward $392, creating a clear trade opportunity.
My thesis: this is a tactical buy. The Novartis result raises scientific and execution questions for the class, but Amgen's valuation, cash generation, dividend, and balance-sheet metrics support buying the pullback for a mid-term trade. I expect the market to differentiate Amgen from trial-specific binary risk and to reward steady cash-flow generation and dividend returns once headline noise cools.
What Amgen does and why the market should care
Amgen is a leading biopharmaceutical company focused on human therapeutics across oncology, inflammation, cardiovascular disease and rare diseases. The company is not a development-stage biotech dependent on a single compound; it is a diversified commercial organization with scale manufacturing, durable margin profile and recurring revenue streams.
Key company metrics investors should note:
- Market capitalization: $211.54 billion.
- Current share price: $392.33 (recent close near $393.17).
- Free cash flow: $10.175 billion.
- Price-to-earnings: ~24x (EPS approximately $16.17).
- EV/EBITDA: 15.8x and EV: $254.85 billion.
- Dividend: $2.52 per share; yield ~2.52%; payable 09/11/2026; ex-dividend 08/21/2026.
Why this selloff is actionable
On 09/07/2026 Novartis announced that pelacarsen failed to meet the primary cardiovascular endpoint. Amgen's stock fell ~5% the following session on broad concern for the Lp(a) mechanism's ability to translate biomarker lowering into clinical benefit. The logical response for active traders is to separate idiosyncratic phase III binary risk from the enduring fundamentals of a cash-generative enterprise. Amgen checks multiple boxes for a swing trade:
- Strong cash generation: $10.175B free cash flow provides support for buybacks, dividends and R&D even if near-term program risks increase investor uncertainty.
- Reasonable multiples for a defensive biopharma: P/E ~24x and EV/EBITDA ~15.8x put valuation in a range that can re-rate if clinical headlines decouple from core revenue stability.
- Dividend and yield: $2.52 per share supports income-minded buyers; dividend payable 09/11/2026 is a near-term cash return event.
- Technical set-up: RSI ~36 suggests the stock is near oversold territory; 50-day SMA sits at about $398, making current levels a tactical entry against short-term support.
Valuation framing
At a market cap of $211.5B and enterprise value of $254.85B, Amgen trades at roughly 24x trailing earnings and about 15.8x EV/EBITDA. For a diversified biotech with $10.2B in free cash flow and a 2.5% yield, these multiples are not exuberant; they reflect a mix of stable cash flows and pipeline risk. Price-to-book sits at 18.1x, which is elevated because book value understates intangible assets and years of R&D investment. In plain terms: the market is not pricing Amgen like a struggling developer — it is applying a normal to slightly conservative multiple range that can expand if the company demonstrates continued revenue resilience and the olpasiran story decouples from the Novartis outcome.
Trade plan (actionable)
Entry: Buy AMGN at $392.33.
Stop loss: $365.00.
Target: $435.00.
Horizon: Primary: mid term (45 trading days). Secondary: if holding through broader clarity on olpasiran or stronger macro rotation into healthcare, extend to long term (180 trading days).
Rationale for horizon: a mid-term (45 trading days) timeframe lets the market digest subsequent trial readouts, analyst commentary and post-Novartis repricing. If the stock stabilizes and catalysts (see below) materialize, the position can be held to 180 trading days to capture a more complete re-rating or further dividend accumulation.
Why the numbers make sense
If AMGN returns to its 50-day range and market sentiment normalizes, a move to $435 is achievable — this price lies well below the 52-week high of $447.03 but materially above current levels, representing a reasonable swing given Amgen's cash generation and income profile. The $365 stop is just under obvious technical support and preserves capital if the stock breaks down further amid sector-wide de-risking.
Catalysts
- Analyst re-writes and conference calls that differentiate olpasiran from pelacarsen and provide clearer readthroughs for Amgen's program.
- Upcoming earnings or guidance commentary that underscores stable revenue and free cash flow generation.
- Dividend payable on 09/11/2026 which can attract income buyers rotating toward healthcare names.
- Sector rotation into defensive names if macro uncertainty increases (energy and geopolitics have destabilized markets recently).
Risks and counterarguments
- Clinical readthrough risk: The Novartis miss on 09/07/2026 may indicate a class-wide issue for Lp(a) lowering translating to clinical outcomes. If olpasiran's phase III data disappoint or its timeline is delayed, the valuation could reset lower.
- Regulatory and payer pressure: Recent policy moves (expanded MFN agreements discussed in headlines) increase pricing scrutiny. While these deals focus mainly on government plans, any step-up in pricing pressure could compress margins over time.
- High leverage metrics: Debt-to-equity is ~4.9, signaling meaningful leverage on the balance sheet. In a stressed macro or financing environment, elevated leverage can limit strategic flexibility.
- Technical momentum and short activity: Short-volume spikes on 09/08/2026 and 09/09/2026 show aggressive short positioning; a continued wave of shorting could pressure the tape and create further downside before a short-covering bounce.
- Counterargument: You could argue the market is correctly re-pricing the entire Lp(a) class and that the failure raises fundamental doubts about translation of biomarker reductions to hard endpoints. In that scenario, even a cash-generative incumbent like Amgen should trade at a discount until the company proves its program's clinical benefit.
What would change my mind
I would move to neutral or sell if Amgen's own trial readouts show negative signals for olpasiran, or if upcoming quarterly results reveal material revenue or margin deterioration tied to competitive pressure or pricing reforms. Conversely, stronger-than-expected clinical readouts on olpasiran, demonstrable sales momentum, or clear guidance for capital return acceleration (larger buybacks) would push me to a stronger bullish rating.
Practical trade mechanics and position sizing
This is a tactical swing trade: consider sizing such that the stop loss at $365 limits downside to a tolerable portion of portfolio risk (e.g., 1-2% portfolio risk per position, adjusted for account risk tolerance). Monitor short volume and sector headlines closely; be prepared to tighten the stop if volume or price action indicates sustained weakness below the $365 level.
Bottom line
The Novartis-driven selloff created a favorable entry into a profitable, dividend-paying biopharma. Amgen's $10.2B free cash flow, $211.5B market cap, mid-20s P/E, and a ~2.5% dividend yield anchor the bull case. The primary risk remains clinical readthroughs for the Lp(a) class and macro/pricing pressures. For traders comfortable with that binary overlay, buying AMGN at $392.33 with a $365 stop and a $435 target over a mid-term (45 trading days) horizon offers an asymmetrical reward profile.